These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
41 related articles for article (PubMed ID: 21946206)
1. [Follow-up study on refractory schizophrenia with brain stereotaxis therapy]. Cai Y; Kuang W; Guo T; Huang H; Wu Z; Zhou B; Zhu Y; Chen X; Li B; Chen H Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2011 Sep; 36(9):876-80. PubMed ID: 21946206 [TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up of mri-guided bilateral anterior capsulotomy in patients with refractory schizophrenia. Liu W; Hao Q; Zhan S; Li D; Pan S; Li Y; Lin G; Pan G; Mahyoub R; Sun B Stereotact Funct Neurosurg; 2014; 92(3):145-52. PubMed ID: 24818571 [TBL] [Abstract][Full Text] [Related]
3. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345 [TBL] [Abstract][Full Text] [Related]
4. The EPPIC follow-up study of first-episode psychosis: longer-term clinical and functional outcome 7 years after index admission. Henry LP; Amminger GP; Harris MG; Yuen HP; Harrigan SM; Prosser AL; Schwartz OS; Farrelly SE; Herrman H; Jackson HJ; McGorry PD J Clin Psychiatry; 2010 Jun; 71(6):716-28. PubMed ID: 20573330 [TBL] [Abstract][Full Text] [Related]
5. Disability in schizophrenia: clinical correlates and prediction over 1-year follow-up. Alptekin K; Erkoç S; Göğüş AK; Kültür S; Mete L; Uçok A; Yazici KM Psychiatry Res; 2005 Jun; 135(2):103-11. PubMed ID: 15923043 [TBL] [Abstract][Full Text] [Related]
6. A comparison of SF-6D and EQ-5D utility scores in a study of patients with schizophrenia. McCrone P; Patel A; Knapp M; Schene A; Koeter M; Amaddeo F; Ruggeri M; Giessler A; Puschner B; Thornicroft G J Ment Health Policy Econ; 2009 Mar; 12(1):27-31. PubMed ID: 19346564 [TBL] [Abstract][Full Text] [Related]
7. N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial. Berk M; Copolov D; Dean O; Lu K; Jeavons S; Schapkaitz I; Anderson-Hunt M; Judd F; Katz F; Katz P; Ording-Jespersen S; Little J; Conus P; Cuenod M; Do KQ; Bush AI Biol Psychiatry; 2008 Sep; 64(5):361-8. PubMed ID: 18436195 [TBL] [Abstract][Full Text] [Related]
8. A pilot double-blind sham-controlled trial of repetitive transcranial magnetic stimulation for patients with refractory schizophrenia treated with clozapine. de Jesus DR; Gil A; Barbosa L; Lobato MI; Magalhães PV; Favalli GP; Marcolin MA; Daskalakis ZJ; Belmonte-de-Abreu Pda S Psychiatry Res; 2011 Jul; 188(2):203-7. PubMed ID: 21186062 [TBL] [Abstract][Full Text] [Related]
9. Nonresponse to clozapine and premorbid functioning in treatment of refractory schizophrenia. Kelly DL; Feldman S; Boggs DL; Gale E; Conley RR Compr Psychiatry; 2010; 51(3):298-302. PubMed ID: 20399340 [TBL] [Abstract][Full Text] [Related]
10. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)]. Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451 [TBL] [Abstract][Full Text] [Related]
11. Early fluoxetine treatment of post-stroke depression--a three-month double-blind placebo-controlled study with an open-label long-term follow up. Fruehwald S; Gatterbauer E; Rehak P; Baumhackl U J Neurol; 2003 Mar; 250(3):347-51. PubMed ID: 12638027 [TBL] [Abstract][Full Text] [Related]
12. Prediction of medication noncompliance in outpatients with schizophrenia: 2-year follow-up study. Yamada K; Watanabe K; Nemoto N; Fujita H; Chikaraishi C; Yamauchi K; Yagi G; Asai M; Kanba S Psychiatry Res; 2006 Jan; 141(1):61-9. PubMed ID: 16318875 [TBL] [Abstract][Full Text] [Related]
13. Neurocognitive and clinical predictors of functional outcome in patients with schizophrenia and bipolar I disorder at one-year follow-up. Tabarés-Seisdedos R; Balanzá-Martínez V; Sánchez-Moreno J; Martinez-Aran A; Salazar-Fraile J; Selva-Vera G; Rubio C; Mata I; Gómez-Beneyto M; Vieta E J Affect Disord; 2008 Aug; 109(3):286-99. PubMed ID: 18289698 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials. Citrome L; Meng X; Hochfeld M; Stahl SM Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738 [TBL] [Abstract][Full Text] [Related]
15. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder. Rossi A; Bagalà A; Del Curatolo V; Scapati F; Bernareggi MM; Giustra MG; Hum Psychopharmacol; 2009 Oct; 24(7):574-83. PubMed ID: 19790173 [TBL] [Abstract][Full Text] [Related]